Tempest Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Tempest Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 509% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-22.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 57% of Healthcare companies in United States.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 74% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Tempest Therapeutics, Inc. made a loss over the last year. Tempest Therapeutics, Inc. owes $1.11 for every $1 it owns. Tempest Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossTempest Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-8.09Tempest Therapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$9 MThe total market value of all of Tempest Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
NegativeTempest Therapeutics, Inc.'s net worth is negative ($1 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-931.1%Tempest Therapeutics, Inc. lost 931.1% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
Owes vs Owns
1.11×Tempest Therapeutics, Inc. owes $1.11 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Dividend yield
NoneTempest Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossTempest Therapeutics, Inc. made a loss in each of the last two years.
Interest cover
Not coveredTempest Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtTempest Therapeutics, Inc. had $0 M more debt than cash (net debt) at Dec 2025.
Questions
What is Tempest Therapeutics, Inc.'s return on equity?
Tempest Therapeutics, Inc. lost 931.1% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
How much does Tempest Therapeutics, Inc. owe compared with what it owns?
Tempest Therapeutics, Inc. owes $1.11 for every $1 it owns, so it owes more than it owns, higher than 90% of Healthcare companies in United States.
Does Tempest Therapeutics, Inc. pay a dividend?
No. Tempest Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.